Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

ANNOUNCEMENT OF BOARD RESOLUTION

The board (the "**Board**") of directors (the "**Directors**") of Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司) (the "**Company**") has recently convened the Eighth Meeting of the Fourth Session of the Board (the "**Meeting**") by way of correspondence voting.

The Board hereby announces that a resolution in relation to the proposed acquisition of part of the equity interest in Valgen Medtech (the "**Proposed Acquisition**") (the "**Resolution**") was considered and approved at the Meeting. Details of the Resolution are set out below:

I. BACKGROUND TO THE PROPOSED ACQUISITION

To further enrich the Company's product pipeline in the structural heart disease sector and achieve the Company's more comprehensive product coverage in this sector, thereby enhancing its overall competitiveness and long-term development potential in the cardiovascular intervention sector, the Company intends to acquire up to 90% of the equity interest in Valgen Holding Corporation by way of equity transfer for a consideration of not more than RMB1,500 million.

Hangzhou Valgen Medtech Co., Ltd., a wholly-owned subsidiary of Valgen Holding Corporation (collectively with Valgen Holding Corporation, "**Valgen Medtech**"), is a research and development enterprise focusing on atrioventricular valve diseases, particularly interventional therapy technologies and products for mitral and tricuspid valves. Four products independently developed by Valgen Medtech have passed the special review procedures for innovative medical devices (green channel products) of the National Medical Products Administration, namely the MitralStitch® transapical mitral valve repair system, the DragonFly™ transcatheter mitral valve clip system, the

DragonFly-T® transcatheter tricuspid valve clip system and the DragonFire® transcatheter myocardial radiofrequency ablation system. Among these, the DragonFly™ transcatheter mitral valve clip system is the first domestically developed transcatheter mitral valve product approved for marketing by the National Medical Products Administration.

II. AUTHORIZATION FOR THE PROPOSED ACQUISITION

The Board has approved the authorization of the Company's chairman to negotiate with Valgen Medtech and its shareholders regarding the content and terms of the agreement of intent for the acquisition and the formal acquisition agreement within the aforementioned acquisition amount and acquisition ratio, amend and finalize the final acquisition ratio and the final draft of the agreement, and sign the relevant agreements and documents on behalf of the Company and affix the Company's seal where necessary.

The Board believes that the Proposed Acquisition, if materialized, will be in line with the Group's strategic development plan in the field of structural heart diseases. Pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the Proposed Acquisition (if materialized) may constitute a discloseable transaction of the Company. The Company will make further announcement(s) regarding any material progress of the Proposed Acquisition in due course, and will comply with all applicable requirements under Chapter 14 of the Listing Rules.

There is uncertainty over the Proposed Acquisition. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC
28 April 2026

As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Dr. Song Yuan, Mr. Wang Ruiqin, Ms. Chen Hongqin and Mr. Zhang Hong as non-executive Directors, and Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.

* *For identification purposes only*